Journal of neuroimaging : official journal of the American Society of Neuroimaging
-
Review Case Reports
Hirayama disease: Nosological classification and neuroimaging clues for diagnosis.
Hirayama disease (HD) is a rare, benign, and nonprogressive motor neuron disease (MND) affecting the upper limbs. It usually presents with weakness and amyotrophy in a single upper extremity with an insidious onset between adolescence and the third decade of life. Since its description in 1959, HD has been known under several names and eponyms in Europe and in Asian countries probably due to its heterogeneous clinical features. ⋯ Also, we report a case of a 18-year-old boy who presented to our Clinic complaining of muscle weakness of the left distal upper limb without other neurological signs. The cervical MRI, in the neutral position, revealed a high T2 signal intensity in the C5-C7 cervical myelomeres as well as the loss of cervical lordosis, whereas, during neck flexion, it showed the anterior displacement of the posterior dura ad the post-gadolinium T1-weighted imaging enhancement of the posterior epidural plexus. These findings are typical for HD allowing the diagnosis as well as the differential diagnosis from other neuromuscular diseases.
-
Objective diagnosis and prognosis in major depressive disorder (MDD) remains a challenge due to the absence of biomarkers based on physiological parameters or medical tests. Numerous studies have been conducted to identify functional magnetic resonance imaging-based biomarkers of depression that either objectively differentiate patients with depression from healthy subjects, predict personalized treatment outcome, or characterize biological subtypes of depression. While there are some findings of consistent functional biomarkers, there is still lack of robust data acquisition and analysis methodology. ⋯ Novel acquisition techniques, such as multiband and multiecho imaging, and neural network-based cleaning approaches can enhance the signal quality in limbic and frontal regions. More comprehensive analyses, such as directed or dynamic functional features or the identification of biological depression subtypes, can improve objective diagnosis or treatment outcome prediction and mitigate the heterogeneity of MDD. Overall, these improvements in functional MRI imaging techniques, processing, and analysis could advance the search for biomarkers and ultimately aid patients with MDD and their treatment course.
-
The tauopathies are a heterogeneous group of neurodegenerative disorders in which the prevailing underlying disease process is intracellular deposition of abnormal misfolded tau protein. Diseases often categorized as tauopathies include progressive supranuclear palsy, chronic traumatic encephalopathy, corticobasal degeneration, and frontotemporal lobar degeneration. Tauopathies can be classified through clinical assessment, imaging findings, histologic validation, or molecular biomarkers tied to the underlying disease mechanism. ⋯ The imaging characteristics will be outlined with select examples of emerging imaging techniques. Finally, current treatment options and emerging therapies will be discussed. This is by no means a comprehensive review of the literature but is instead intended for the practicing radiologist as an overview of a rapidly evolving topic.
-
Ultra-high-field 7.0 Tesla (T) MRI offers substantial gains in signal-to-noise ratio (SNR) over 3T and 1.5T, but for over two decades has remained a research tool, while 3T scanners have achieved widespread clinical use. This much slower translation of 7T relates to daunting technical challenges encountered in ultra-high-field human MR imaging. The recent introduction of United States Food and Drug Administration (FDA)-approved clinical 7T scanners promises to be a watershed for many 7T neuroimaging applications, including epilepsy imaging. ⋯ We describe a tiered epilepsy imaging strategy and protocols designed to optimize 7T value and work around signal intensity variation and signal loss artifacts, which remain significant challenges to full exploitation of 7T clinical value. We describe FDA-approved techniques for mitigating these artifacts and briefly outline techniques currently under development, but not yet FDA approved. Finally, we discuss the major issues in 7T patient safety and toleration, outlining their physical causes and effects on workflow, and provide references to more comprehensive technical reviews for readers seeking greater technical detail.
-
Angiocentric gliomas (AGs) are epileptogenic low-grade gliomas in young patients. We aimed to investigate the MRI findings of AGs and systematically review previous publications and three new cases. ⋯ Intratumoral T1-weighted high-intensity areas, stalk-like signs, and regional brain atrophy were frequent imaging features in AG. We also found that affected age was different between supratentorial and brainstem AGs.